Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes.

Cancer Manag Res · 2020 · PMC7221413 · PMID 32440212

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might not be significantno p-value reported

32 , 35 , 43 , 45 The survival benefit of trastuzumab might not be significant in survival analyses for tumors with TILs ≥ 50% or 60%.

also in 673 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.